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Abstract 
Understanding the mechanisms of neurodegeneration is crucial for development of therapies to treat 
neurological disorders. S100 proteins are extensively expressed in the injured brain but S100's role and 
signalling in neural cells remain elusive. We recently demonstrated that the S100A4 protein protects neurons 
in brain injury and designed S100A4-derived peptides mimicking its beneficial effects. Here we show that 
neuroprotection by S100A4 involves the growth factor family receptor ErbB4 and its ligand Neuregulin 1 
(NRG), key regulators of neuronal plasticity and implicated in multiple brain pathologies. The neuroprotective 
effect of S100A4 depends on ErbB4 expression and the ErbB4 signalling partners ErbB2/Akt, and is reduced by 
functional blockade of NRG/ErbB4 in cell models of neurodegeneration. We also detect binding of S100A4 with 
ErbB1 (EGFR) and ErbB3. S100A4-derived peptides interact with, and signal through ErbB, are neuroprotective 
in primary and immortalized dopaminergic neurons, and do not affect cell proliferation/motility - features which 
make them promising as potential neuroprotectants. Our data suggest that the S100-ErbB axis may be an 
important mechanism regulating neuronal survival and plasticity. 
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Introduction 
Understanding the mechanisms of neurodege-
neration and identification of novel pro-survival 
signalling cascades is crucial for development of 
therapies to treat neurological disorders. Neuregulin 1 
(NRG) and its receptor ErbB4 are among the most 
important regulators of neuronal survival and 
plasticity in brain pathologies. The ErbB4 receptor 
tyrosine kinase is expressed in hippocampal and 
dopaminergic neurons and cerebellar granule cells, as 
well as in glia[1, 2], and is upregulated in multiple 
neurological disorders[2-7] with a prominent 
overexpression observed in neuronal populations of 
the affected brain areas including peri-injury regions 
in ischemia[4] and brain trauma[7], dopaminergic 
neurons in midbrain of Parkinson's disease 
patients[3], and hippocampal neuritic plaques in 
Alzheimer's disease[5]. ErbB4 mainly links to the 
Ras-MAPK and PI3K-Akt pathways (reviewed in [1, 
2]). Thereby, activated ErbB4 promotes neurogenesis, 
neuronal differentiation and survival[2, 8-11] exerting 
neuroprotective effects in models of cerebral ischemia, 
and Alzheimer’s and Parkinson’s diseases[1, 8, 12-15]. 
NRG-ErbB4 signalling also regulates synaptic 
function and neuronal excitability[2], and disruption 
of this cascade has been shown to be a key factor in 
the development of epilepsy[6, 16] and schizophrenia 
[1, 17, 18]. 
Recently, we have characterized a broad spect-
rum trophic factor in the nervous system, the S100A4 









mediated signalling. S100A4 was initially identified as 
a metastasis promoter and a prognostic marker in 
several cancer types[20, 21], but is also expressed by 
and secreted from non-malignant cells regulating 
their migration, differentiation and survival [19, 22, 
23] and is markedly (over)expressed in the CNS after 
brain injury in rodents or humans[19, 24-26]. S100A4 
belongs to a large multifunctional S100 protein family 
(currently 21 members) known to regulate a plethora 
of cell functions in tissues such as muscle, lung, bone 
and intestine acting both intra- and extracellularly[21, 
27]. However, despite at least 12 members of the 
family being expressed in the healthy and injured 
nervous system, the role and signalling of S100 
proteins in the brain remain poorly understood. 
Likewise, signalling by extracellular S100A4 
remains largely unexplored and presumably involves 
both a common S100 target receptor for advanced 
glycation end products (RAGE) and other, yet 
unidentified receptors[28]. Previously, we have 
demonstrated that extracellular S100A4 promotes 
neurite extension in a RAGE-independent mode[29, 
30], and that S100A4 also protects neurons against 
oxidative stress and apoptosis in vitro and in animal 
models of brain trauma and epilepsy, thus emerging 
as a broad spectrum neuroprotectant in the CNS[19]. 
These beneficial effects of S100A4 were mirrored in 
vitro and in vivo by two peptide mimetics of S100A4 
that we designed, H3 and H6, encompassing the 
neurotrophic motifs of the protein. The H3-peptide 
shared high homology within the S100 family and the 
H6-peptide represented a low-homology ('unique') 
motif in the C-terminal of S100A4[19, 31]. The 
peptides protected neurons in cell and animal models 
of traumatic brain injury and excitotoxicity, as well as 
against genetically induced peripheral nerve 
degeneration[19, 31]. Intriguingly, neuroprotection by 
S100A4 was not mediated by RAGE either, and 
another putative target for S100A4 that we have 
identified, the interleukin-10 (IL-10) receptor, was 
only partially involved[19], strongly suggesting the 
existence of additional neurotrophic pathways for 
S100A4. To determine these pathways, we indentified 
two important previous findings: (i) S100A4 activates 
both Ras-MAPK and PI3K-Akt cascades in 
neurons[19, 30] and (ii) S100A4 affects EGFR 
(ErbB1)/ErbB2 signalling in mouse embryonic 
fibroblasts[32]. Based on this data, we hypothesised 
that the mechanism behind the neuroprotective effect 
of S100A4 involves ErbBs of one, or more subtypes. 
Here we show that S100A4 uses the 
ErbB4/ErbB2 signalling axis to increase neuronal 
survival. We also demonstrate that S100A4 binds to 
the ErbB4 ligand NRG and that the S100A4/NRG 
interaction is important for neuroprotection by 
S100A4. Furthermore, peptides derived from neuro-
trophic sites of S100A4 protect neurons in cell models 
of Parkinson's disease and interact with/signal 
through ErbB. The peptides do not affect cell 
proliferation or motility making them promising 
candidates for development of specific neuroprotect-
ive therapies. Together, our findings for the first time 
link the S100 family proteins with the ErbB signalling 
cascade, suggesting a novel mechanism of neuro-
protection in the injured brain, and introduce S100A4 
peptide derivatives as neuroprotectants potentially 
suitable for a broad range of therapeutic applications. 
Results 
S100A4 binds to and exerts its pro-survival 
effect via ErbB receptors 
The involvement of ErbB receptors in S100- 
induced effects in neural cells has not been reported 
on previously; however, our earlier results indicated 
that S100A4 signal through ErbB1 in fibroblasts[32]. 
We therefore investigated whether trophic effects of 
S100A4 in neurons can also be mediated by ErbBs. As 
a test system, we used cultured hippocampal neurons, 
which express ErbB receptors [1, 33, 34] and in which 
S100A4 is known to induce neuritogenesis and 
increase survival during oxidative stress[19, 29, 30]. 
The general ErbB kinase inhibitor PD158780 did not 
affect the S100A4-induced neurite outgrowth (Fig 1A), 
but blocked the pro-survival effect of S100A4 in 
neurons treated with an oxidative stress inducer H2O2 
(Fig 1B), indicating that the S100A4-induced 
neuroprotection depends on ErbBs, whereas neurite 
extension promoted by S100A4 is likely mediated by 
other mechanism(s). Since ErbB2 is only known to 
signal in complex with other ErbB receptors[1], these 
results also suggested that S100A4 could bind ErbB1, 
3, or 4 with ErbB2 possibly serving as a linker to 
downstream signalling cascades. Corroborating this 
suggestion, knockdown of ErbB2 in vitro abolished 
neuroprotection by S100A4 (Fig 1C). Interestingly, 
S100A4 also increased neuronal survival rates in 
cultures electroporated with control shRNA but not 
treated with H2O2 (Fig 1C) most probably reflecting 
the protein counteracting the decrease in neuronal 
viability following transfection. To further study the 
S100A4-ErbB interaction, we performed label transfer 
cross-linking experiments of S100A4 with ErbB1-4 
receptors in solution (see Materials and Methods for 
details). We observed transfer of the biotin label to 
ErbB1, ErbB3 and ErbB4 (Fig 1D), indicating complex 
formation between S100A4 and these receptors. No 
S100A4 binding with ErbB2 or control antibodies 
(IgG) was detected (Fig 1D). Since label transfer only 
qualitatively detects protein interactions with the 





intensity of visualized bands not directly reflecting 
the binding affinity, we quantitatively investigated 
the S100A4-ErbB binding using surface plasmon 
resonance analysis (SPR). S100A4 directly interacted 
with ErbB1, ErbB3 and ErbB4 in SPR (Fig 1E, Suppl 
Fig 1A) binding to ErbBs immobilized on a sensor 
chip with the apparent affinities S100A4:ErbB1/ 
ErbB3/ErbB4, Kd = 21.4 ± 5.5/58.0 ± 30.0/66.0 ± 26.9 
nM, calculated based on binding kinetics. No 
S100A4-ErbB2 binding was detected (Fig 1E). Taken 
together, this data indicated that S100A4 interaction 
with ErbBs could be the mechanism behind the 
pro-survival effect of S100A4 in neurons. 
S100A4-induced neuronal survival involves 
ErbB4 and its ligand neuregulin 
We next set out to clarify the involvement of 
ErbB1 (EGFR) and ErbB4 in the S100A4-induced 
neuroprotection. Two selective pharmacological 
inhibitors of EGFR did not affect the neurotrophic 
effect of S100A4 in the oxidative stress model (Fig 1F, 
G). To inhibit the function of ErbB1, 3 and 4, we used 
previously described neutralizing antibodies to these 
receptors[35-37]. Neither anti-EGFR, nor anti-ErbB3 
antibodies significantly inhibited the S100A4-induced 
neuroprotection even though weak evidence towards 
decreased neuronal survival was observed (p = 0.25 
and p = 0.15, Fig 1H). In agreement with earlier 
reports, the anti-ErbB4 antibodies blocked the 
pro-survival effect of the ErbB4 native ligand 
neuregulin (NRG), but not that of the EGFR ligand 
amphiregulin (AR), thus specifically distinguishing 
between the EGFR- and ErbB4-mediated signalling 
pathways (Fig 1I). These antibodies did not bind to 
S100A4 itself, as demonstrated by SPR (Suppl Fig 1B; 
positive control, RAGE, a known binding partner of 
S100A4), but inhibited the neuroprotective effect of 
S100A4 without affecting the basal neuronal viability 
(Fig 1J), suggesting the involvement of ErbB4 in 
neuroprotection by S100A4. We, therefore, next 
investigated whether the neuroprotective effect of 
S100A4 correlated with the level of ErbB4 expression 
in hippocampal neurons. To this end, we utilized 
previous findings demonstrating that (i) ca 15-20% of 
cultured hippocampal neurons express detectable 
levels of ErbB4 at 10 DIV[38] thus providing a ‘natural 
knockout’ model for this receptor, and (ii) that ErbB4 
is upregulated during neurodegeneration and by 
oxidative stress[4, 7, 39]. In our setup, hippocampal 
neurons (10-12 DIV) were treated with H2O2 for 24 h 
in the presence or absence of S100A4 and double 
stained for ErbB4 and the nuclear marker Hoechst. 
Confocal images of ErbB4 expressing cells were 
binarized at an arbitrary threshold of 0.25×maximal 
(saturating) brightness in all image series and cells 
detectable at this threshold were designated as those 
with moderate/high ErbB4 expression (ErbB4(+)). 
The remaining cells were designated as those with 
low/absent ErbB4 expression (ErbB4(-)). Confirming 
previously published data, ca. 25% of untreated 
hippocampal neurons exhibited moderate/high 
ErbB4 expression (Fig 2A). In agreement with 
previous reports, ErbB4 expression was markedly 
upregulated by the oxidative stress induced by H2O2, 
the rate of ErbB4(+) cells increasing nearly two-fold 
(Fig 2B). Interestingly, we also found suggestive 
evidence that treatment with S100A4 alone may 
increase the number of ErbB4-expressing cells, which, 
however, did not reach statistical significance (p=0.08, 
Fig 2B). Accordingly, ErbB4 mRNA was upregulated 
by S100A4 nearly 3-fold in cultured neurons (Fig 2C, 
see Suppl Fig 2A for primer sequences). We have also 
detected the ErbB3 mRNA, albeit the level of 
expression was low and remained unaffected by 
S100A4 treatment (Fig 2C). 
We subsequently compared the pro-survival 
effect of S100A4 in ErbB4(-) and ErbB4(+) neurons 
subjected to H2O2-induced oxidative stress. In 
ErbB4(+) cells, S100A4 was significantly neuroprote-
ctive (Fig 2D, upper panel). Cells with low expression 
of ErbB4 could not be efficiently protected by S100A4, 
though there was a slight evidence towards increased 
survival (p=0.21, Fig 2D, lower panel) suggesting 
possible involvement of other receptor (sub)types. 
Thus, the S100A4-ErbB4 axis could represent a 
'hidden' neuroprotective mechanism activated as a 
result of S100A4 and ErbB4 overexpression following 
neuronal damage, with ErbB4 levels possibly also 
modulated by extracellular S100A4 released from glial 
cells. 
We have previously shown that S100A4 is 
upregulated by brain trauma and that S100A4- 
deficient mice are more susceptible to neuronal 
damage following brain injury[19]. We thus examined 
whether expression of S100A4 and ErbB4 correlate in 
the normal and injured brain. ErbB4 levels in motor 
cortex of the S100A4-/- and the wild-type (WT) mice 
were not significantly different (Fig 2E, Sham, p=0.19). 
In mice subjected to unilateral cryogenic brain injury, 
the number of ErbB4-positive cells was significantly 
lower in S100A4-/- compared to WT mice on the 
contralateral (undamaged) side (Fig 2E, CL). 
Ipsilaterally, ErbB4 was strongly upregulated in both 
WT and S100A4-/- animals, in agreement with 
previous reports demonstrating pronounced increase 
in ErbB4 levels after brain injury[3, 4, 7] (Fig 2E, IL). 
Thus, ErbB4 expression was affected by brain injury 
and also correlated with S100A4 levels on the 
contralateral side of the injured brain. 





To further investigate the involvement of ErbB4 
in the S100A4-induced neuronal survival we knocked 
down expression of ErbB4 in hippocampal neurons 
(Fig 2F). We found that both neuroprotection induced 
by S100A4 and by its 'unique' C-terminal motif H6 
were decreased by ErbB4 silencing (Fig 2F, see Suppl 
Fig 1B for peptide sequences). In S100A4-treated cells, 
this inhibition was rescued by the activator of Akt, a 
downstream kinase of the ErbB receptor signalling 
pathway (Fig 2F), thus corroborating the role of ErbB4 
in the pro-survival effect of S100A4. 
S100A4-ErbB4/Neuregulin signalling confers 
neuroprotection in models of neuronal injury 
Neuregulins (NRGs) are major ligands of ErbB 
receptors. Immature NRGs are transmembrane 
proteins, which upon proteolysis release soluble 
N-terminal fragments interacting with and activating 
ErbBs and launching signalling cascades to regulate 
neural development, plasticity and survival[40]. 
Neuregulin-1, in particular, has been associated with 
neuronal survival in several brain pathologies 
including AD, PD and ischemia[8, 13-15, 41]. Since we 
have previously shown that S100A4 interacts with the 
ErbB1 (EGFR) ligand amphiregulin (AR)[32] but the 
S100A4-NRG interaction under native conditions has 
not been investigated, we next tested the specific 
hypothesis whether S100A4 could also bind NRG. 
Confirming previously published data, S100A4 
immobilized on a sensor chip interacted with soluble 
AR in the SPR assay with the Kd = 71.3 ± 12.3 nM (Fig 
2G, left). In the same experimental setup, S100A4 also 
bound with soluble NRG (Kd = 19.9 ± 3.9 nM, Fig 2G, 
right). 
To confirm the role of NRG in neuroprotection 
by S100A4, we used inhibitory antibodies to NRG, 
which specifically blocked the neurotrophic effect of 
NRG, but not of AR, in the H2O2-treated cultures (Fig 
2H, left). In the same experimental setup, anti-NRG 
antibodies abolished the S100A4-induced neuro-
protection without affecting basal neuronal survival 
(Fig 2H, right). These results suggested that formation 
of the functional S100A4/ErbB4/NRG 'unit' might be 
necessary for S100A4 to protect neurons against 
prolonged oxidative stress (24 h in our setup). We 
then investigated the relative roles of ErbB4 and NRG 
in neuroprotection by S100A4 at the initial stage of 
neurotoxicity. Similar to long-term experiments, 
neuronal death induced by the 2 h exposure to H2O2 
was strongly decreased by S100A4 treatment (Fig 2I). 
However, the neuroprotective effect of S100A4 was 
only inhibited by the pharmacological ErbB4 blocker, 
but not by the neutralizing anti-NRG antibodies (Fig 
2I). Thus, NRG was ostensibly dispensable for the 
S100A4-induced pro-survival signalling during the 
early stage of neurotoxicity. 
If the neuroprotective effect of S100A4 
specifically involves its interaction with NRG/ErbB4, 
interference would be expected between the S100A4- 
and NRG-induced survival pathways, whereas the 
AR/EGFR-mediated survival should be independent 
of S100A4. Indeed, the neuroprotective effects of 
S100A4 and AR were clearly additive in neurons 
subjected to oxidative stress (Fig 2J, left). However, no 
additive effect was observed in cultures concomi-
tantly treated with S100A4 and NRG, suggesting that 
the two proteins utilized significantly overlapping 
survival pathways (Fig 2J, right). 
Interestingly, neither ErbB4-, nor NRG-neutra-
lizing antibodies had any effect on the S100A4- 
induced neurite outgrowth (Fig 2K). Thus, the 
S100A4-NRG/ErbB4 axis presumably represented a 
'survival-tuned' signalling mechanism, which could 
be common for many types of neuronal injury. 
Indeed, we obtained similar results in another 
physiologically relevant in vitro model of brain 
damage, in which neuronal death was evoked by 
kainic acid (KA), an excitotoxic agent inducing 
neuropathology characteristic for human temporal 
lobe epilepsy in rodent in vivo models[19]. Confirming 
our previous findings[19], S100A4 robustly protected 
hippocampal neurons in this model, and this effect 
was abrogated by both anti-ErbB4 and anti-NRG 
neutralizing antibodies (Fig 2L). 
S100A4 and its peptide derivatives are 
neurotrophic in primary and immortalized 
dopaminergic neurons, the pro-survival effect 
involving ErbB4 
We next explored whether the S100A4-NRG/ 
ErbB4 signalling could be a mechanism behind the 
neuroprotective effect of the protein in other neuronal 
populations. It has previously been shown that 
S100A4 induces neurite outgrowth in dopaminergic 
neurons[42] and protects them from cell death 
following exposure to 6-hydroxydopamine 
(6-OHDA), the neurotoxin which reproduces major 
pathological hallmarks of PD in animals, including 
selective dopaminergic degeneration, dopamine 
depletion, oxidative stress, and neurobehavioral 
deficits[43]. Neurotrophic peptide mimetics of 
S100A4, H3 and H6, have been shown to protect 
neurons in cell and animal models of traumatic brain 
injury and excitotoxicity[19] but have not been 
characterized in models of PD. Supporting earlier 
reports, S100A4 was neuritogenic in dopaminergic 
neurons, and its peptide derivatives induced neurite 
extension comparable with that triggered by the 
parent protein (Fig 3A, staining for dopaminergic 
neuron marker tyrosine hydroxylase (TH), quantified 





in Fig 3B). All three compounds also had a robust 
pro-survival effect in the 6-OHDA neurotoxicity 
model in dopaminergic neurons (Fig 3C). 
Interestingly, the H3- and H6-peptides only mimicked 
the neuroprotective, but not the metastasis/ 
invasion-related effects of S100A4 in vitro. S100A4, 
known to increase invasiveness of astrocytic tumour 
cells[44], promoted migration and, to a lesser extent, 
proliferation of cultured human brain glioblastomas 
(LN229). In contrast, the peptides had no effect on 
these parameters in either micromolar (Fig 3D, E) or 
nanomolar (Fig 3F) range of concentrations. We then 
investigated whether H3 and H6 interacted with and 
exerted their pro-survival effect via ErbBs. 
Interestingly, both peptides bound the immobilized 
ErbB1, ErbB3 and ErbB4 in the SPR experiments (Fig 
3G), albeit with affinities lower than that of the parent 
protein (Kd values H3:ErbB1/ErbB3/ErbB4, 106.8 ± 
23.1/202.8 ± 46.7/198.6 ± 53.1 nM; H6:ErbB1/ 
ErbB3/ErbB4, 802.2 ± 114.5/62.3 ± 18.8/217.3 ± 19.9 
nM). H3 and H6 had comparable affinities to ErbB4; 
however, H6 had lower affinity to ErbB1 and higher 
affinity to ErbB3 than H3. Because both peptides 
interacted with ErbB4, we next examined whether 
their pro-survival effect in hippocampal neurons 
involved this receptor. The H6-induced neuroprotec-
tion was decreased by the ErbB4 neutralizing 
antibodies, but the H3-induced survival was not 
significantly affected (Fig 3H) suggesting that the H6 
(C-terminal) motif of S100A4 may be important for 





Fig. 1. S100A4 interacts with ErbB receptors and protects neurons in vitro via ErbB2 and ErbB4. (A, B) Pharmacological blocker of ErbB (PD158780) does not affect the 
S100A4-induced neurite outgrowth (A), but abolishes the pro-survival effect of S100A4 in the H2O2-treated neurons (B). The ErbB inhibitor alone (A, B, ■) has no effect. Ctl, neurite 
outgrowth from untreated controls; Inh, treatment with PD158780 (20 µM) alone. In (A, B), S100A4 is used at 20 µM, four independent experiments. (B) CTL, neuronal viability in untreated 
controls, ANOVA vs cultures treated with H2O2 and S100A4 in the absence of inhibitor (A4). (C) Knockdown of ErbB2 reduces S100A4-induced neuroprotection (A4, 20 µM). For shRNA 
treatment, the survival of transfected neurons was normalized to untreated controls (100%). *, vs untreated; #, S100A4-untreated vs S100A4-treated cells, two-way ANOVA. Here and 
henceforth, results are expressed as means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. (D) S100A4 interacts with ErbB receptors in solution. Immunoblot of the cross-linked 
Sulfo-SBED-S100A4 and Fc-fusion constructs of ErbB1, 2, 3, 4 or mouse immunoglobulin G (IgG) and cross-linked. Representative of two independent experiments. (ctl) Binding of 
sulfo-SBED-S100A4 to Protein A beads with no prey (negative control). Lower panel, loading controls. IgG, double band corresponds to partially reduced heavy and light IgG chains. (E) SPR 
binding of S100A4 to immobilized ErbB1, 2, 3 and 4, representative of two independent experiments. (F, G) Pharmacological blockers of EGFR PD153035 (F) and AG1478 (G) do not inhibit 
the pro-survival effect of S100A4 in neurons subjected to oxidative stress in vitro. The EGFR inhibitors alone (F, G, ■) have no effect. (H) Inhibitory antibodies to EGFR or ErbB3 do not have 
a significant effect on the S100A4-induced survival in the H2O2-treated (□) or untreated (■, Ab) neurons, four to five independent experiments. (I) Inhibitory antibodies to ErbB4 (Ab) do not 
decrease neuroprotective effect of EGFR ligand amphiregulin (AR), but specifically block neuroprotection by the ErbB4 ligand neuregulin (NRG). (J) Inhibitory antibodies to ErbB4 abolish the 
pro-survival effect of S100A4 in the H2O2-treated neurons. Antibodies alone (■, Ab) have no effect. H-J, CTL, neuronal viability in untreated controls, ANOVA vs cultures treated with H2O2 
and S100A4 in the absence of antibodies (A4). 






Fig. 2. The S100A4-induced neuroprotection involves ErbB4 and neuregulin. (A, B) ErbB4 expression in hippocampal neurons is upregulated by oxidative stress (H2O2). (A), 
representative confocal images of hippocampal neurons, treated with H2O2, S100A4 or H2O2 +S100A4 (10 µM) for 24 h. Double staining ErbB4 and Hoechst to detect pyknotic nuclei. Images 
of ErbB4 expressing cells are binarized with a threshold of 0.25 of maximal brightness (see text for details). (B) ErbB4-expressing neurons are more resistant to oxidative stress compared to 
non ErbB4-expressing cells. Expression is normalized to untreated controls (100%), two-way ANOVA with Tukey’s post-test, *, vs untreated, four independent experiments. (C) Treatment 
with S100A4 (20 µM, 24 h) upregulates the ErbB4, but not the ErbB3 mRNA in cultured hippocampal neurons, assessed by qPCR. Paired t-test, three to four independent experiments. (D) 
Pro-survival effect of S100A4 in neurons with moderate/high or low expression of ErbB4 (ErbB4(+) and ErbB4(-), respectively) following H2O2-induced oxidative stress. CTL, neuronal viability 
in controls not treated with S100A4, two-way ANOVA with Tukey’s post-test, four independent experiments. (E) ErbB4 expression in the motor cortex (sham-operated animals) or in the 
sublesion zone after cryolesion ipsi- (IL) and contralateral (CL) to traumatic brain injury in WT and S100A4-/- mice (KO), representative images and quantification. LZ, lesion zone. Number 
of animals, 8/6/4 (WT/KO/Sham). Two-way ANOVA, *, vs CL WT; #, vs Sham WT. (F) Left, representative confocal images of untreated (CTL) or ErbB4 siRNA-transfected (siErbB4) 
hippocampal neurons. White arrowheads indicate low- or non-ErbB4-expressing cells. Right, knockdown of ErbB4 reduces S100A4- and H6-induced neuroprotection (A4, H6, 20 µM). For 
siRNA treatment, the survival of transfected neurons was normalized to untreated controls (100%). *, vs untreated; #, S100A4-untreated vs S100A4- treated cells, two-way ANOVA. (G) SPR 
binding of amphiregulin (AR) or neuregulin (NRG) to the immobilized S100A4, representative of three independent experiments. RB, running buffer. (H) Inhibitory antibodies to neuregulin 
(Ab) specifically decrease neuroprotective effect of neuregulin (NRG) without affecting that of amphiregulin (AR) (left) and abolish neuroprotection by S100A4 in the H2O2-treated neurons 
(right). Antibodies alone (□) have no effect. (I) Neuroprotection by S100A4 (20 µM) depends on ErbB, but not on NRG at an early stage of neurotoxicity (2 h of H2O2 treatment). Assessed 
by Hoechst staining in living hippocampal neurons, ErbB inh (PD158780), αNRG, inhibitory antibodies to NRG. *, vs untreated; #, vs H2O2 only- treated cells, two-way ANOVA, three 
independent experiments. (J) Neuroprotection by S100A4 (A4, ■) is additive with the pro-survival effect of amphiregulin (AR, □, left), but not with that of neuregulin (NRG, □, right). (I, J). 
CTL, neuronal viability in untreated controls, one-way ANOVA vs cultures treated with H2O2 and S100A4 in the absence of antibodies (A4), four independent experiments. (K) Inhibitory 
antibodies to ErbB4 (left) or NRG (right) do not affect the S100A4-induced neurite outgrowth (■). Ctl, neurite outgrowth from untreated controls. Neither antibodies stimulated neurite 
extension from the control neurons when applied alone (K, □). One-way ANOVA vs S100A4 alone-treated cultures, four independent experiments. (L) Inhibitory antibodies to ErbB4 or NRG 
abolish the pro-survival effect of S100A4 in the KA-treated neurons. CTL, neuronal viability in untreated controls, set to 100%. *, vs CTL; #, vs KA only- treated cells, two-way ANOVA, four 
independent experiments. 






Fig. 3. S100A4 and its peptide derivatives act as neuritogenic and pro-survival factors in dopaminergic neurons. (A, B) S100A4 (5 µM) and S100-derived peptides (H3, H6, 5 
µg/ml) induce neurite outgrowth from dopaminergic neurons (representative images of TH-immunostained cultures (A), quantified in (B)). (C) S100A4, H3 and H6 protect dopaminergic 
neurons from OHDA-induced death. CTL (100%), the survival rate in the untreated controls. One-way ANOVA, * vs unstimulated cultures (B, neurite outgrowth) or treated with OHDA 
only (C, survival), four independent experiments. (D-F) H3 and H6 do not promote migration or proliferation of cultured human glioblastoma cells either in high (D, E) or low (F) 
concentrations. CTL (100%), the migration/proliferation rate in the untreated controls. One-way ANOVA, * vs unstimulated cultures, four to six independent experiments. (G) SPR binding 
of H3 and H6 peptides to immobilized ErbB1, ErbB3 and ErbB4, representative of two independent experiments. (H) Inhibitory antibody to ErbB4 partially decrease the H6-induced 
pro-survival effect in cultured neurons subjected to oxidative stress. CTL, neuronal viability in untreated controls, one-way ANOVA vs cultures treated with H2O2 and S100A4 in the absence 
of antibodies. 





To further investigate S100A4 signalling in 
dopaminergic cells, we employed the neuronal cell 
line N27 composed of immortalized TH- and 
dopamine transporter-positive fetal mesencephalic 
neurons[45, 46], providing a useful in vitro model of 
dopaminergic neurodegeneration [43, 46, 47]. 
Neurotrophic effects of S100A4 and its derivatives 
were fully reproduced in this system: S100A4, H3 and 
H6 promoted neurite outgrowth in N27 (Fig 4A) and 
were protective in a dose-dependent manner against 
cell toxicity induced by H2O2 (Fig 4B) and 6-OHDA 
(Fig 4C). 
ErbB4 is known to be overexpressed in PD, and a 
similar effect is observed in toxin-based in vitro PD 
models ([3] and references therein). In our 
experimental system, exposure to 6-OHDA resulted 
in more than a 2-fold increase in the number of N27 
cells with moderate to high ErbB4 expression (Fig 4D, 
quantified in Fig 4E). Similar to the hippocampal 
neurons, the protective effect of S100A4 in N27 cells 
involved ErbB4: neutralizing antibodies to the 
receptor reduced the anti-apoptotic effect of S100A4 
in the 6-OHDA model (Fig 4F) without affecting basal 
neuronal viability. The anti-ErbB4 antibodies also 
reduced the S100A4-induced phosphorylation of Akt, 
the kinase involved in canonical neurotrophic 
signalling pathways downstream of ErbB4[40] and in 
pro-survival signalling of S100A4 in hippocampal 
neurons[19] (Fig 4G). Thus, the ErbB4-PI3K-Akt 
cascade was at least partially responsible for trophic 
effects of S100A4 in N27 cells, suggesting that the 
S100A4-NRG/ErbB4 signalling may be involved in 
the S100A4-induced neuroprotection in several 
neuronal types. 
Discussion 
In summary, we establish S100A4 as a signalling 
partner of ErbB4, demonstrate that the NRG/ErbB4 
axis is important for pro-survival effect of S100A4 and 
explore biochemical and neurotrophic properties of 
S100A4-derived peptides. Three key aspects of our 
findings are to (i) provide a mechanism for the 
previously observed neuroprotective effect of S100A4 
in the injured brain, (ii) for the first time link S100A4 
with the NRG/ErbB4/ErbB2 signalling cascade in 
several cell models, and (iii) introduce S100A4 
derivatives H3 and H6 as broad spectrum 




Fig. 4. Neuroprotective effect of S100A4 in N27 dopaminergic cells is dependent on ErbB4. (A-C) S100A4 (5 µM) and S100-derived peptides (H3, H6, 5 µg/ml) promote neurite 
outgrowth from N27 cells (A) and protect N27 from H2O2-induced oxidative stress (B) and OHDA-induced toxicity (C). (D, E) Exposure to OHDA (100 µM, 24 h) increases the ratio of N27 
cells with moderate/high expression of ErbB4 (see text for details). Representative images of cells double stained for ErbB4 and Hoechst to detect pyknotic nuclei (D), evaluated in (E), four 
independent experiments. (F) Inhibitory antibodies to ErbB4 reduce neuroprotection by S100A4 in the OHDA-treated N27 cells. Antibodies alone (■) have no effect. CTL, neuronal viability 
in untreated controls, one-way ANOVA vs cultures treated with H2O2 and S100A4 (A4) in the absence of antibodies. (G) S100A4-induced phosphorylation of Akt in N27 (A4, 10 µM) is 
decreased by inhibitory ErbB4 antibodies (αErbB4), five independent experiments. CTL (100%), neurite outgrowth (A), survival rate (B, C, F), ErbB4 expression (E), or actin-normalized 
phAkt levels (G) in the untreated controls. Two tailed t-test * vs CTL (E); ANOVA, * vs CTL (A, F), H2O2-treated (B) or OHDA-treated (C) cultures, ## vs A4 (G). (H) Signalling mechanisms 
involved in the S100A4-induced neuronal survival. Schematic representation of putative S100A4-NRG-ErbB functional complexes (I, II, see text for details). 
 
 





As we have previously shown, S100A4 robustly 
protects neurons in animal models of brain trauma 
and epilepsy, and this effect is readily reproduced in 
corresponding in vitro models, in which neuronal 
death is induced by oxidative stress or KA 
excitotoxicity[19]. Our results indicate that in both of 
these models, neuroprotection by S100A4 involves 
ErbB4/NRG signalling. Moreover, these results also 
provide an explanation of our previous findings 
showing that S100A4 activates the Ras-MAPK- and 
Akt- associated signalling in neurons[19], since ErbB4 
links to both of these pathways[1, 2]. 
Interestingly, our data suggest that to exert its 
pro-survival effect, S100A4 interacts with and utilizes 
both ErbB4 and its ligand NRG. This is reminiscent of 
our previous findings[32] showing that S100A4 
activates EGFR and interacts with its ligand 
amphiregulin thereby enhancing the amphiregulin- 
mediated proliferation of mouse embryonic 
fibroblasts. However, only ErbB4, but not NRG was 
indispensable for neuroprotection against short-term 
neurotoxicity (2h oxidative stress) suggesting that 
whereas induction of neuroprotection by S100A4 may 
only require ErbB4, NRG is needed for prolonged 
effect of the protein. We speculate that NRG may 
stabilize the S100A4/ErbB4 complex and/or be 
recruited to ErbB4 by the S100A4 protein to act as a 
co-agonist (Fig 4H). Given that NRG is initially 
synthesized as a membrane-anchored precursor 
which is then shed into the extracellular space, at least 
two modes of S100A4/NRG/ErbB4 interaction may 
exist with both transmembrane (Fig 4H, I) and soluble 
forms of NRG (Fig 4H, II ) involved in the complex. 
Although involvement of ErbB4 in pro-survival 
effects of S100A4 in vivo needs further clarification, 
accumulating data point to the importance of the 
S100A4-ErbB signalling axis in brain pathologies. 
There is a high similarity between the biological 
effects of S100A4 and the native ErbB4 ligand NRG in 
models of brain damage: both proteins act as 
antioxidants, decrease neuronal death and attenuate 
excitotoxicity[16, 19, 48]. We have also found that 
ErbB4 expression was higher in the contralateral 
hemisphere of S100A4 WT compared to KO animals 
following injury (Fig 2E). Interestingly, we have also 
previously detected a post-traumatic contralateral 
upregulation of S100A4[19], both effects most 
probably following the spreading astrocytic 
activation, which occurs in focal brain injuries[49, 50] 
and was also observed in our cryogenic lesion 
model[19]. Moreover, as it was recently demonstrated 
in a mouse brain injury model and human brain 
astrocytes, spreading astroglyosis can affect and be 
reciprocally regulated by the activation of ErbB 
receptors in reactive astrocytes[51, 52]. Since S100A4 
can be released from stressed astrocytes[19] and 
upregulate ErbB4 mRNA in cultured neurons (Fig 
2C), S100A4 present in the CL hemisphere of WT 
animals with brain injury might directly and/or by 
affecting astroglyosis modulate contralateral ErbB4 
expression. Taken together, these findings suggest 
that the two proteins may create 'hot loci' in the 
injured brain in which S100A4 released from stressed 
or lysed astrocytes and/or blood cells[19] may locally 
bind to and activate neuronal ErbB4 receptors. Such 
cooperation would be facilitated by the pattern of the 
proteins’ expression in brain pathologies, with both 
S100A4 and ErbB4 strongly upregulated at sites of 
brain injury[1, 3, 4, 7, 19]. S100A4 distribution 
depends on the type of brain insult, with traumatic 
brain injury resulting in S100A4 increase in the 
underlying cortex and diffuse KA-induced 
excitotoxicity leading to S100A4 upregulation in the 
hippocampus[19]. To our knowledge, no studies have 
to date addressed extracellular concentrations of 
S100A4 in vivo. However, our quantitative data on the 
S100A4 release from cultured astrocytes (≈0.02-0.2 
ng/ml for 2 mm diffusion layer[19]) allows us to 
estimate the effective S100A4 concentration in the 
extracellular space (~20 nm) to be in the range of 2-20 
μg/ml, which is sufficiently high for the protein to 
exert its biological effects. ErbB4 expression is also 
strongly dependent on physiological and pathological 
context and is likely wider than that observed in vitro. 
In particular, while in rodent hippocampal cultures 
ErbB4 is predominantly detected in interneurons, in 
the human brain, ErbB4 is also robustly expressed by 
hippocampal pyramidal neurons in AD, and, to a 
lesser extent, in age-matched controls[39]. ErbB4 is 
also upregulated in the midbrain of PD patients[3] 
and was shown to be essential for neuroprotection in 
knockout mouse models of PD[15]. Activation of 
ErbB4 suppresses limbic epileptogenesis[16] and 
protects against ischemic brain injury in animal 
models[41]. Thus, the S100A4-induced ErbB4 
modulation may potentially play a role in many brain 
disorders, holding promise for future therapeutic 
applications. Indeed, S100A4 mimetics that we have 
previously developed and demonstrated to be 
neuroprotective in animal models of brain trauma and 
epilepsy, also proved efficient in two in vitro models 
of PD (Fig 3C, 4B, C). Importantly, S100A4 derivatives 
only mimicked neurotrophic, but not invasion-related 
properties of the parent protein (Fig 3D-F) thus 
making them suitable for further development as 
drug candidates. The peptides have also provided an 
insight in the mechanism of S100A4-ErbB interaction. 
In our experiments, H3 and H6 bound with ErbB4 
with similar affinities; however, H6 had a 
significantly lower affinity to ErbB1 and higher 





affinity for ErbB3 than H3. Moreover, inhibition of 
ErbB4 diminished the H6- but not H3-induced 
neuroprotection (Fig 3H). Given that H3 represents a 
common motif in S100 proteins and H6 is a C-terminal 
motif unique for S100A4 these results suggests that: (i) 
several S100 proteins may interact with ErbB 
receptors and (ii) in the environment where multiple 
types of ErbB are available, S100A4 may have a 
preference for ErbB3/ErbB4 receptors, as compared to 
ErbB1. 
Further structural studies and ErbB4 targeting 
strategies in vivo will be required to validate the 
S100A4/ErbB4/NRG axis in the brain. However, 
here, we for the first time link the S100 family protein 
with the ErbB signalling cascade in neurons. Given 
that ErbBs are involved in multiple brain functions 
such as neuronal differentiation, glia development, 
neurogenesis, and synaptic transmission, S100A4 
could potentially modulate these processes. 
Interesting possibilities are S100A4 modulating the 
ErbB4-mediated synaptic plasticity, which is involved 
in cognition and memory formation [2], or S100A4 
regulating the ErbB4-mediated neurogenesis, since 
both proteins are expressed at sites of neurogenesis 
[19, 24, 53, 54]. 
The focus of this study was the S100A4-ErbB4 
functional link. However, our results suggest that 
S100A4 signalling may also involve other pro-survival 
receptors, in particular ErbB1 and/or ErbB3, which 
are similarly to ErbB4 associated with PI3K/Akt and 
ERK pathways and could provide a complementary 
pro-survival route depending on relative ErbB levels 
and physiological context. Indeed, neuronal ErbB 
expression has previously been reported in several 
brain regions including the developing and/or adult 
hippocampus[34, 55-58]. However, scarce data is 
available on the ErbB distribution in specific neuronal 
populations in vitro and in vivo depending on species, 
developmental stage and, importantly, the presence 
of neuronal injury. ErbBs are also abundantly 
expressed in astrocytes and can be modulated by 
reactive astroglyosis, thus providing an additional 
route for S100A4-ErbB signalling which may be 
particularly important in human brain where the 
relative astrocyte content is markedly higher than in 
rodents. Moreover, since a number of other S100 
proteins are expressed in the nervous system and 
share homology with S100A4, the S100-ErbB axis may 
represent an important mechanism regulating 
neuronal survival and plasticity. 
Materials and Methods 
Peptides and recombinant proteins 
Peptides (sequences H3: KELLTRELPSFLGKRT, 
H6: NEFFEGFPDKQPRKK) were synthesized as 
tetramers composed of four monomers coupled to a 
lysine backbone (Schafer-N, Denmark). Tetrameriza-
tion was previously found to be necessary for the 
neuritogenic activity of S100A4[30]. Recombinant 
S100A4 was produced as described in [30, 59]. EGF, 
AR, NRG1 as well as Fc-conjugated ErbB1, 2,3,4 were 
purchased from R&D Systems (R&D, US) as a carrier 
free product. 
Cell lines and animals 
The rat immortalized mesencephalic dopamine-
rgic neuronal cell line 1RB3AN27 (N27) was used, 
derived from day 12 rat fetal mesencephalic tissue 
and composed of immortalized cells positive for 
tyrosine hydroxylase[45]. N27 cells were grown in 
RPMI 1640 medium supplemented with 10% FBS, 
penicillin (100 U/mL), and streptomycin (100 
μg/mL). All experiments were performed between 
passages 11 and 20 and at 50-80% confluence in RPMI 
1640 with 1% serum. 
Animals were handled in accordance with 
European Union legislation (European Directive 
2010/63/EU). Pregnant Wistar rats (E13 or E18) were 
from Charles River (Denmark or UK). S100A4-/- mice 
on an A/Sn background (8-10 wks) were generated 
and genotyped as described in [60], and were not 
phenotypically different from WT A/Sn mice, used as 
controls. Traumatic brain injury in mice and tissue 
preparation were performed as previously 
described[19]. 
Neuronal survival assay 
Rat hippocampal (E19) and midbrain (E13) 
cultures were prepared according to [61] and [42], 
respectively. After 7 DIV, hippocampal neurons were 
treated with AR, NRG1 or S100A4 for 1 h, challenged 
with KA (300 µM) or H2O2 (60 µM, both from Sigma 
Aldrich, Copenhagen, Denmark), further cultured for 
24 h, fixed, and stained with Hoechst 33258 
(Invitrogen). Inhibitory antibodies to ErbB4 or NRG 
(both from Neomarkers, Fremont, CA), EGFR (D1D4J, 
Cell Signalling), ErbB3 (2F12, Thermo Fisher), the 
pan-ErbB inhibitor (PD158780, Merck, Millipore A/S, 
Hellerup, Denmark), or EGFR inhibitors (PD153035, 
AG1478, both from Sigma) were added 30 min prior 
to S100A4, NRG, or AR. For knockdown experiments, 
hippocampal neurons were prior to plating 
electroporated[62] with 2 µg plasmid DNA encoding 
shRNA for rat ErbB2 or nontargeting shRNA 
(OriGene, Rockville, MD, USA), both cloned in pGFP 
plasmid. Alternatively, neurons (5 DIV) were 
transfected with 5 pMol of Stealth RNAi™ siRNA 
(1330001, ThermoFisher) mixed with 0.5 µg 
pmaxGFP-encoding plasmid (Lonza) using 
Lipofectamin 2000 (Invitrogen) in serum- and 
antibiotics-free medium according to manufacturer’s 





protocol. After 3 DIV (shRNA) or 2 DIV (siRNA), 
neurons were consecutively treated with S100A4 or 
H6 and H2O2 as described above, further cultured for 
24 h and stained with Hoechst 33258. Akt activator 
(SC79, Calbiochem, 4 µM) was added 1 h prior to 
H2O2. To confirm the knockdown of ErbB4, neurons 
were stained with rabbit-anti-Erb4 antibodies (Santa 
Cruz, sc-33040, 1:200) followed by Alexa Fluor 
568-conjugated goat anti-rabbit antibody. Images 
were acquired using a Zeiss (Carl Zeiss, Germany) 
LSM 510 confocal laser-scanning microscope with an 
oil immersion 63×1.4NA objective (Carl Zeiss). To 
quantify the numbers of surviving transfected 
neurons, the cells were counterstained for GFP, the 
total number of cells did not differ between the 
groups. To evaluate neuronal survival in the presence 
and absence of ErbB4, hippocampal cultures (10 DIV) 
were treated with S100A4 (5 µg/ml) for 1 h followed 
by H2O2 (60 µM), cultured for 24 h and double stained 
with Hoechst 33258 and anti-ErbB4 antibodies (Ab77, 
Thermo-Fisher, UK). Midbrain cultures were grown 
for 12 days, treated with S100A4, H3 or H6 for 1 h 
followed by OHDA (100 µM), further cultured for 24 h 
and immunostained with polyclonal anti-Tyrosine 
Hydroxylase (TH) antibodies (PA5, 1:1000, 
Thermo-Fisher, UK) to identify dopaminergic 
neurons. 
To evaluate neuronal survival, 25 (hippocampal 
neurons) or 50 (dopaminergic neurons) images were 
recorded randomly for each group in each experiment 
employing a Nikon Eclipse E800 microscope with a 
Nikon Plan ×20 objective (Nikon, Tokyo, Japan) 
coupled to a video camera (QImaging, Surrey, 
Canada). Images were acquired using the ImagePro 
software (Media Cybernetics, Rockville, USA). 
Neuronal survival was evaluated as the ratio of live 
(non-pyknotic) neurons to the total number of 
neurons (hippocampal, Hoechst staining) or as an 
average number of TH-positive neurons per image 
(dopaminergic, TH staining) using the PlabApp 
software (Protein Laboratory, University of 
Copenhagen, Denmark, 2002) as previously described 
[62, 63]. The obtained viability levels were normalized 
to those in untreated controls (CTL, set to 100%). 
Neurite outgrowth assay 
Freshly isolated hippocampal or midbrain 
neurons were plated in 8-well LabTek Permanox 
slides (NUNC, Denmark or UK, coated with 1 µg/ml 
laminin for 24 h at 37°C for midbrain cultures) at a 
density of 10,000 (hippocampal) or 100,000 (midbrain) 
cells per well, stimulated with serially diluted S100A4, 
H3 or H6 and grown for 24 h. Whenever applicable, 
pharmacological blockers and inhibitory antibodies 
were added 30 min prior to S100A4. After 24 h in vitro, 
hippocampal cultures were stained with Coomassie 
Blue R250 and midbrain cultures were immuno-
stained for TH as described above. Neurite outgrowth 
was evaluated using computer-assisted microscopy as 
described in [61]. 
ErbB4 expression studies and confocal 
microscopy 
Hippocampal cultures were grown for 12 days, 
treated with H2O2 for 24 h in the presence or absence 
of S100A4 (10 µM) and co-stained for Hoechst to 
detect pyknotic nuclei and ErbB4 as described above. 
Images of at least 200 neurons for each group in each 
experiment were obtained with a Leica Laser 
Scanning System 2000 coupled to a Nikon Eclipse TE 
200 confocal microscope equipped with an 
oil-immersion 60×1.4-NA objective (Nikon, Tokyo, 
Japan). To ensure quantitative comparability, 
stainings were performed concurrently for all 
treatments and acquisition parameters were kept 
constant throughout recording for each experiment. 
In all recorded series, background-subtracted images 
of ErbB4-expressing neurons were binarized at an 
arbitrary threshold of 0.25×maximal brightness 
(calculated from all images recorded in the 
experiment), and detected cells were designated as 
‘neurons with moderate to high ErbB4 expression’ 
(ErbB4(+)). The remaining cells were designated as 
‘neurons with low ErbB4 expression’ (ErbB4(-)). 
Sulphorhodamine B (SRB) proliferation assay 
Human glioblastoma cell line LN229 was 
cultured in DMEM (Gibco) supplemented with 10% 
FBS (Gibco) in a 5% CO2 humidified incubator at 
37°C. Cells were seeded in 96-well plates (Corning, 
New York, USA) at 2×103 cells per well in DMEM 
supplemented with 2% FBS. Twenty-four hours 
post-plating LN229 cells were treated with S100A4, 
H3, or H6 for 72 h. Cells were then fixed with 10% 
tri-chloroacetate (TCA) for at least 1 h at 4°C, washed 
4 times with distilled water and allowed to air dry 
before being stained with 0.4% w/v SRB (Sigma) for 
1h. Since SRB is light sensitive, staining was done 
concurrently on all plates to ensure comparable 
results. Plates were washed with 0.1% acetic acid to 
remove unbound SRB and air-dried. Bound SRB was 
dissolved in 10 mM Tris pH 10.5 and the absorbance 
was measured at 490nm using an EL×800 microplate 
reader (BioTek, Vermont, USA). Absorbance values 
were normalised to untreated controls. 
Wound healing migration assay 
LN229 cells were plated into wound healing 
inserts (Ibidi, Munich, Germany) at a density of 
1.7×104 cells per insert well (7.7×104 cells/cm2) in 





DMEM supplemented with 10% FBS. Twenty four 
hours post-plating inserts were removed, wells 
washed with warm PBS and cells treated with H3, H6 
or S100A4 in DMEM supplemented with 1% FBS for 8 
h. Cells were fixed with 10% TCA for at least 1 h at 
4°C and stained with SRB as described above. Images 
of the gap were captured using a TMS inverted phase 
contrast microscope (Nikon) with a DinoEye AM7023 
eyepiece camera (AnMo Electronics, Taipei, Taiwan). 
Migration rate was evaluated as a percentage of the 
gap area covered by migrated cells using ImageJ 
software package (U. S. National Institutes of Health, 
Bethesda, Maryland, USA). 
Histology and morphometric analysis 
Animal perfusion and brain processing were 
performed as previously described[64]. Immuno-
histochemistry was performed on 7 μm coronal 
sections as described in[19, 64] using the anti-ErbB4 
primary antibodies (1:400; Chemicon, HFR1/2G4), 
followed by Alexa Fluor-conjugated (Invitrogen) 
secondary antibodies. Negative controls were 
prepared identically, but the primary antibody was 
omitted. 
Images were acquired using an Olympus BX-51 
microscope and the Visiopharm Integrator System 
software (Visiopharm). Quantifications were perfor-
med in the sublesion area (3 sections per animal, 
Sham/KO/WT, n =4/6/8) using the computer- 
assisted Stereological Toolbox program with unbiased 
sampling (CAST-2, Olympus) by a researcher blind to 
treatment. 
qRT-PCR analysis of ErbB expression 
Hippocampal neurons (3×106) were seeded in 30 
mm tissue culture dishes, cultured for 7 days and 
treated with 10 µM S100A4. Total RNA preparation, 
qRT-PCR and data analysis were performed as 
described previously[65], primer sequences are 
shown in Suppl Fig 2A. All samples were run in 
duplicates. The relative levels of the PCR products in 
all samples were evaluated by the Pfaffl method using 
GAPDH as a house keeping gene [66]. 
S100A4-ErbB binding in solution, label transfer 
cross-linking assay 
To study S100A4-ErbB interactions, human 
recombinant S100A4 and EGF (positive control) were 
derivatized with sulfo-N-hydroxysuccinimidyl-2-(6- 
[biotinamido]-2-(p-azido benzamido)-hexanoamido) 
ethyl-1,3'-dithioproprionate (sulfo-SBED, Pierce) as 
specified by the manufacturer’s protocol. The 
biotin-linker incorporation was estimated by using a 
Biotin Quantitation Kit (Pierce) according to 
supplier’s protocol. 
For the photochemical cross-linking Sulfo-SBED- 
conjugated proteins (100 nM) were incubated in dark 
for 30 min at RT with 50 nM EGFR-Fc, ErbB2-Fc, 
ErbB3, ErbB4-Fc, or as control mouse IgG (Sigma) in 
100 μL TBS-Ca2+. To cross-link interacting proteins, 
the samples were irradiated with UV light (302 nm) 
for 5 min. Resulting complexes were precipitated with 
Protein A-coupled magnetic Dynabeads (Invitrogen). 
The beads were subsequently washed four times with 
500 μL ice-cold TBS/0.1% Triton X-100. To elute 
precipitated proteins and to cleave the cross-linker 
spacer arm, the beads were resuspended in 50 μL 1x 
reducing sample buffer (50 mM Tris-HCl (pH 6.8), 2% 
SDS, 10% glycerol, 100 mM DTT and 0.1% 
bromphenol blue) and boiled for 5 min at 95°C. 
Samples were placed on magnet and supernatants 
were transferred to clean tubes, before loading on a 
6% SDS-PAGE for Western blot analysis. Pierce High 
Sensitivity Streptavidin-HRP (1:10000; Thermo 
Scientific) was used to detect the protein bands with 
biotin label, and loading control bands were detected 
by protein A-HRP (1:16000; Thermo Scientific). 
Immunoblotting assay 
N27 cells (10×106 cells) were grown in low-serum 
(1%) culture medium for 24 h before treatment. 
Immunoblotting was performed as described 
previously [29]. Rabbit anti-phospho-Akt antibodies 
(1:1000; Invitrogen) or rabbit anti-β-actin (1:5000; 
Sigma) were used. Akt phosphorylation was 
normalized to β-actin levels for each sample. 
SPR analysis 
SPR experiments were conducted on a BIAcore 
2000 system (GE-Healthcare Life Sciences, Upsala, 
Sweden). To study protein-protein and protein- 
peptide interactions, 2000 resonance units (RU) of 
recombinant human S100A4, the human extracellular 
ErbB1/Fc, ErbB3/Fc, or ErbB4/Fc chimera (R&D 
Systems) were immobilized covalently on a CM4 
sensor chip (Biacore). Binding and data analysis were 
performed as described previously[29]. For each 
condition, two to three independent experiments 
were performed. 
Statistics 
Statistics was performed using Origin 8 software 
(OriginLab) and GraphPad Prism 6 (GraphPad 
software, Inc., La Jolla, CA, USA) by two-tailed t-test, 
one-way ANOVA or two-way ANOVA with Tukey’s, 
Dunnett or Sidak post-tests to identify statistically 
significant groups. Unless indicated otherwise, results 
are expressed as means ± SEM, *p < 0.05; **p < 0.01; 
***p < 0.001. 






6-OHDA, 6-hydroxydopamine; AD, Alzheimer’s 
disease; CNS, central nervous system; ERK, 
extracellular signal regulated kinase; GFP, green 
fluorescent protein; KA, kainic acid; NRG, Neuregulin 
1; PD, Parkinson’s disease; RAGE, receptor for 
advanced glycation end products; SPR, surface 
plasmon resonance. 
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